Full Press Release Details
Media Advisory - Oncolytics Biotech Inc. to Participate in the 14th Annual
Needham Healthcare Conference
CALGARY, April 13, 2015 /CNW/ - Dr. Brad Thompson, President and CEO of
Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will participate in the 14th Annual Needham and Company's Healthcare
Conference in a session on Tuesday, April 14th, 2015 at 2:20 p.m. ET. The conference takes place on April
14th and 15th in New York, NY.
A live audio link to the webcast session will be available at http://wsw.com/webcast/needham71/oncy
or on the company's website at http://www.oncolyticsbiotech.com/for-investors/presentations. It is recommended that
listeners log on 10 minutes in advance of a live session to register and download any necessary software. An audio replay will
be accessible approximately two hours following the presentation on the Oncolytics website.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics.
Oncolytics' clinical program includes a variety of later-stage, randomized human trials in various indications using REOLYSIN ,
its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.
The session and webcast times are subject to change. This release and
the presentation related thereto contain forward-looking statements which involve known and unknown risks, delays, uncertainties
and other factors not under the Company's control and which may cause actual results, performance or achievements of the Company
to be materially different from the results, performance or expectations implied by these forward-looking statements. Such
risks and uncertainties include, among others, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion
of clinical studies and trials, uncertainties related to the research and development of pharmaceuticals and uncertainties related
to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities
commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned
against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements,
except as required by applicable laws.
SOURCE Oncolytics Biotech Inc.
For further information: TMX Equicom, Nick Hurst, 300 5th Ave. SW, 10th
Floor, Calgary, Alberta T2P 3C4, Tel: 403.218.2835, Fax: 403.218.2830, nhurst@tmxequicom.com; TMX Equicom, Michael Moore, San Diego,
CA, Tel: 858.886.7813, mmoore@tmxequicom.com; Dian Griesel, Inc. Susan Forman, 335 West 38th Street, 3rd Floor, New York, NY 10018,
Tel: 212.825.3210, Fax: 212.825.3229, sforman@dgicomm.com
CO: Oncolytics Biotech Inc.
CNW 06:30e 13-APR-15